Long Term Impact of Rapid Intravenous Infusion of Velaglucerase Alfa (VPRIV)

NCT04120506 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Gaucher Disease, Type 1

Interventions

DRUG: VPRIV

Sponsor

Shaare Zedek Medical Center

Collaborators

[object Object]